R. B. Levin

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.

B. G. Rao, Chao Lin, S. Harbeson, 2004, Bioorganic & medicinal chemistry letters.

The “Steroid Dementia Syndrome”: An Unrecognized Complication of Glucocorticoid Treatment

O. Wolkowitz, E. Bigler, S. Lupien, 2004, Annals of the New York Academy of Sciences.

Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogues.

Christopher M Thomas, J. Hoffman, J. Wai, 1992, Journal of medicinal chemistry.

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

P. Darke, W. Schleif, O. M. Blahy, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis, antiviral activity, and bioavailability studies of gamma-lactam derived HIV protease inhibitors.

M. Holloway, J. Vacca, R. Hungate, 1994, Bioorganic & medicinal chemistry.

Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors

P. Anderson, Jiunn H. Lin, P. Darke, 1994 .

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

P. Darke, W. Schleif, J. Quintero, 1994, Journal of medicinal chemistry.

Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.

E A Emini, L. Kuo, P. Darke, 2000, Journal of medicinal chemistry.

Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.

B. G. Rao, S. Harbeson, R. Perni, 2003, Bioorganic & medicinal chemistry letters.

A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.

T. Halgren, M. Holloway, J. Vacca, 1995, Journal of medicinal chemistry.